Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
830.3 USD | +1.21% | +2.64% | +42.24% |
04:21pm | Eli Lilly: encouraging data for olomorasib | CF |
01:55pm | Structure Therapeutics' obesity drug meets main goal in mid-stage study | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.24% | 739B | |
+32.80% | 598B | |
-5.15% | 353B | |
+18.02% | 318B | |
+5.08% | 285B | |
+16.55% | 240B | |
+9.53% | 210B | |
-5.36% | 206B | |
+7.83% | 164B | |
+2.03% | 162B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Eli Lilly and Company's Phase 3 Study of Mirikizumab to Treat Crohn's Disease Achieves 'Meaningful Improvements'